BACKGROUND: The aim of this study was to improve fluorescence laparoscopy of pancreatic cancer in an orthotopic mouse model with the use of a light-emitting diode (LED) light source and optimal fluorophore combinations. STUDY DESIGN: Human pancreatic cancer models were established with fluorescent FG-RFP, MiaPaca2-GFP, BxPC-3-RFP, and BxPC-3 cancer cells implanted in 6-week-old female athymic mice. Two weeks postimplantation, diagnostic laparoscopy was performed with a Stryker L9000 LED light source or a Stryker X8000 xenon light source 24 hours after tail-vein injection of CEA antibodies conjugated with Alexa 488 or Alexa 555. Cancer lesions were detected and localized under each light mode. Intravital images were also obtained with the OV-100 Olympus and Maestro CRI Small Animal Imaging Systems, serving as a positive control. Tumors were collected for histologic analysis. RESULTS: Fluorescence laparoscopy with a 495-nm emission filter and an LED light source enabled real-time visualization of the fluorescence-labeled tumor deposits in the peritoneal cavity. The simultaneous use of different fluorophores (Alexa 488 and Alexa 555), conjugated to antibodies, brightened the fluorescence signal, enhancing detection of submillimeter lesions without compromising background illumination. Adjustments to the LED light source permitted simultaneous detection of tumor lesions of different fluorescent colors and surrounding structures with minimal autofluorescence. CONCLUSIONS: Using an LED light source with adjustments to the red, blue, and green wavelengths, it is possible to simultaneously identify tumor metastases expressing fluorescent proteins of different wavelengths, which greatly enhanced the signal without compromising background illumination. Development of this fluorescence laparoscopy technology for clinical use can improve staging and resection of pancreatic cancer.
BACKGROUND: The aim of this study was to improve fluorescence laparoscopy of pancreatic cancer in an orthotopic mouse model with the use of a light-emitting diode (LED) light source and optimal fluorophore combinations. STUDY DESIGN:Humanpancreatic cancer models were established with fluorescent FG-RFP, MiaPaca2-GFP, BxPC-3-RFP, and BxPC-3cancer cells implanted in 6-week-old female athymic mice. Two weeks postimplantation, diagnostic laparoscopy was performed with a Stryker L9000 LED light source or a Stryker X8000 xenon light source 24 hours after tail-vein injection of CEA antibodies conjugated with Alexa 488 or Alexa 555. Cancer lesions were detected and localized under each light mode. Intravital images were also obtained with the OV-100 Olympus and Maestro CRI Small Animal Imaging Systems, serving as a positive control. Tumors were collected for histologic analysis. RESULTS: Fluorescence laparoscopy with a 495-nm emission filter and an LED light source enabled real-time visualization of the fluorescence-labeled tumor deposits in the peritoneal cavity. The simultaneous use of different fluorophores (Alexa 488 and Alexa 555), conjugated to antibodies, brightened the fluorescence signal, enhancing detection of submillimeter lesions without compromising background illumination. Adjustments to the LED light source permitted simultaneous detection of tumor lesions of different fluorescent colors and surrounding structures with minimal autofluorescence. CONCLUSIONS: Using an LED light source with adjustments to the red, blue, and green wavelengths, it is possible to simultaneously identify tumor metastases expressing fluorescent proteins of different wavelengths, which greatly enhanced the signal without compromising background illumination. Development of this fluorescence laparoscopy technology for clinical use can improve staging and resection of pancreatic cancer.
Authors: Brendon M Stiles; Amit Bhargava; Prasad S Adusumilli; Stephen F Stanziale; Teresa H Kim; Valerie W Rusch; Yuman Fong Journal: Surgery Date: 2003-08 Impact factor: 3.982
Authors: Matthew H Katz; Shinako Takimoto; Daniel Spivack; A R Moossa; Robert M Hoffman; Michael Bouvet Journal: J Surg Res Date: 2003-07 Impact factor: 2.192
Authors: H E Doran; L Bosonnet; S Connor; L Jones; C Garvey; M Hughes; F Campbell; M Hartley; P Ghaneh; J P Neoptolemos; R Sutton Journal: Dig Surg Date: 2004-09-13 Impact factor: 2.588
Authors: Cristina A Metildi; Sharmeela Kaushal; George A Luiken; Robert M Hoffman; Michael Bouvet Journal: J Am Coll Surg Date: 2014-03-02 Impact factor: 6.113
Authors: Ali A Maawy; Yukihiko Hiroshima; Sharmeela Kaushal; George A Luiken; Robert M Hoffman; Michael Bouvet Journal: J Biomed Opt Date: 2013-12 Impact factor: 3.170
Authors: Haiming Luo; Christopher G England; Shreya Goel; Stephen A Graves; Fanrong Ai; Bai Liu; Charles P Theuer; Hing C Wong; Robert J Nickles; Weibo Cai Journal: Mol Pharm Date: 2017-03-24 Impact factor: 4.939
Authors: Cristina A Metildi; Sharmeela Kaushal; Cynthia S Snyder; Robert M Hoffman; Michael Bouvet Journal: J Surg Res Date: 2012-09-07 Impact factor: 2.192
Authors: Cristina A Metildi; Csilla N Felsen; Elamprakash N Savariar; Quyen T Nguyen; Sharmeela Kaushal; Robert M Hoffman; Roger Y Tsien; Michael Bouvet Journal: Ann Surg Oncol Date: 2014-10-16 Impact factor: 5.344
Authors: Cristina A Metildi; Sharmeela Kaushal; Minya Pu; Karen A Messer; George A Luiken; Abdool R Moossa; Robert M Hoffman; Michael Bouvet Journal: Ann Surg Oncol Date: 2014-02-06 Impact factor: 5.344